A Randomized, Double Blind, Phase II Trial of Pazopanib Versus Placebo as Maintenance Therapy in Patients With Retroperitoneal and Visceral High-risk Soft Tissue Sarcomas Following Prior Neo- and/or Adjuvant Doxorubicin / Ifosfamide Chemotherapy With Regional Hyperthermia
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2017
Price : $35 *
At a glance
- Drugs Pazopanib (Primary)
- Indications Sarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms NEOPAMAIN
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2016 Status changed from recruiting to discontinued.
- 09 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.